Lack of Change of Lipoprotein(a) Levels by the Optimization of Glycemic Control With Insulin Therapy in NIDDM Patients

Assumpta Caixàs; Antonio Pérez; Jordi Qrdóñez-Llanos; Rosa Bonet; Mercedes Rigla; Agustina Castellví; L Bayén; Alberto De Leiva

doi:10.2337/diacare.20.9.1459

Original Articles

Lack of Change of Lipoprotein(a) Levels by the Optimization of Glycemic Control With Insulin Therapy in NIDDM Patients

Assumpta Caixàs, MD, PHD,
Antonio Pérez, MD, PHD,
Jordi Qrdóñez-Llanos, MD, PHD,
Rosa Bonet, MSc,
Mercedes Rigla, MD,
Agustina Castellví, RN,
L Bayén, MSc and
Alberto De Leiva, Md, PHD

Department of Endocrinology and Nutrition, Hospital de Sam Pau, Universitat Autdnoma de Barcelona Barcelona, Spain
Department of Biochemistry (Lipid Section), Hospital de Sam Pau, Universitat Autdnoma de Barcelona Barcelona, Spain

Address correspondence and reprint requests to Antonio Pérez Pérez, Servei d'Endocrinologia i Nutrició, Hospital de Sant Pau, Avda Sant Antoni M^a Claret, 167, 08025 Barcelona, Spain

Diabetes Care 1997 Sep; 20(9): 1459-1461. https://doi.org/10.2337/diacare.20.9.1459

Abstract

OBJECTIVE To evaluate the effect of glycemic control improvement with insulin therapy on lipoprotein(a) [Lp(a)] levels in patients with NIDDM.

RESEARCH DESIGN AND METHODS We performed a longitudinal study in a tertiary referral center to compare lipid and Lp(a) levels before and after 3 months of insulin therapy in 60 poorly controlled NIDDM patients (32 men, 28 women). Patients previously treated with oral hypoglycemic agents (n = 50) received one to two insulin doses, and those previously treated with insulin (n = 10) received multiple insulin doses. Lp(a) levels were measured by the Terumo method. Differences between the two periods were assessed by the paired t test and Wilcoxon's test.

RESULTS After 3 months of insulin therapy, HbA_1c decreased from 9.6 ± 1.9 to 6.0 ± 1.4% (P < 0.0005) in all patients and from 9.1 ± 2.1 to 6.1 ± 2.9% (P < 0.05) in patients under multiple insulin doses, being ≤ 6.0% in 59% of patients. Total triglyceride and VLDL cholesterol levels decreased (P < 0.01) and HDL cholesterol increased significantly (P < 0.0005). However, no changes in Lp(a) levels were observed in all patients (25.3 ± 25.0 vs 25.7 ± 27.2% mg/dl) and in patients with baseline Lp(a) levels above (63.5 ± 15.5 vs. 65.1 ± 23.1 mg/dl) or below 30 mg/dl (11.5 ± 7.5 vs. 11.5 ± 7.3 mg/dl). In addition, patients reaching HbA_1c levels ≤ 6.0% or > 6.0% presented similar Lp(a) levels (26.0 ± 29.1 vs 25.3 ± 25.0 mg/dl). Moreover, no correlations were observed between changes in Lp(a) levels and in the glycemic control parameters.

CONCLUSIONS This study shows that the improvement of glycemic control by insulin therapy does not influence plasma Lp(a) levels, measured by the Terumo method, in NIDDM patients, independently of baseline values and the degree of glycemic control reached.